# Covid-19 automated diagnosis and risk assessment through Metabolomics and Machine-Learning

Jeany Delafiori<sup>14</sup>, Luiz Claudio Navarro<sup>24</sup>, Rinaldo Focaccia Siciliano<sup>34</sup>, Gisely Cardoso de Melo<sup>4,5</sup>, Estela Natacha Brandt Busanello<sup>1</sup>, José Carlos Nicolau<sup>3</sup>, Geovana Manzan Sales<sup>1</sup>, Arthur Noin de Oliveira<sup>1</sup>, Fernando Fonseca Almeida Val<sup>4,5</sup>, Diogo Noin de Oliveira<sup>1</sup>, Adriana Eguti<sup>6</sup>, Luiz Augusto dos Santos<sup>7</sup>, Talia Falcão Dalçóquio<sup>3</sup>, Adriadne Justi Bertolin<sup>3</sup>, João Carlos Cardoso Alonso<sup>7,8</sup>, Rebeca Linhares Abreu-Netto<sup>4,5</sup>, Rocio Salsoso<sup>3</sup>, Djane Baía-da-Silva<sup>4,5</sup>, Vanderson Souza Sampaio<sup>4,9</sup>, Carla Cristina Judice<sup>10</sup>, Fabio Trindade Maranhão Costa<sup>10</sup>, Nelson Durán<sup>8</sup>, Mauricio Wesley Perroud<sup>6</sup>, Ester Cerdeira Sabino<sup>11</sup>, Marcus Vinicius Guimarães Lacerda<sup>4,12</sup>, Leonardo Oliveira Reis<sup>13</sup>, Wagner José Fávaro<sup>8</sup>, Wuelton Marcelo Monteiro<sup>4,5</sup>, Anderson Rezende Rocha<sup>2,\*</sup> and Rodrigo Ramos Catharino<sup>1,\*</sup>

¥The authors equally contributed to the work.

<sup>&</sup>lt;sup>1</sup> Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil

<sup>&</sup>lt;sup>2</sup>RECOD Laboratory, Computing Institute, University of Campinas, Campinas, Brazil

<sup>&</sup>lt;sup>3</sup> Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

<sup>&</sup>lt;sup>4</sup> Tropical Medicine Foundation Dr. Heitor Vieira Dourado, Manaus, Brazil

<sup>&</sup>lt;sup>5</sup> Amazonas State University, Manaus, Brazil

<sup>&</sup>lt;sup>6</sup> Sumaré State Hospital, Sumaré, Brazil

<sup>&</sup>lt;sup>7</sup> Paulínia Municipal Hospital, Paulínia, Brazil

<sup>&</sup>lt;sup>8</sup> Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas, Campinas, Brazil

<sup>&</sup>lt;sup>9</sup> Health Surveillance Foundation of Amazonas State, Manaus, Brazil

<sup>&</sup>lt;sup>10</sup> Laboratory of Tropical Diseases, Institute of Biology, University of Campinas, Campinas, Brazil

<sup>&</sup>lt;sup>11</sup> Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil

<sup>&</sup>lt;sup>12</sup> Leônidas and Maria Deane Institute, FIOCRUZ, Manaus, Brazil

<sup>&</sup>lt;sup>13</sup> UroScience Laboratory, University of Campinas, Campinas, Brazil

<sup>\*</sup>Corresponding author: RRC - rrc@unicamp.br; ARR - andersonrocha@ic.unicamp.br.

#### **ABSTRACT**

COVID-19 is still placing a heavy health and financial burden worldwide. Impairments in patient screening and risk management play a fundamental role on how governments and authorities are directing resources, planning reopening, as well as sanitary countermeasures, especially in regions where poverty is a major component in the equation. An efficient diagnostic method must be highly accurate, while having a cost-effective profile.

We combined a machine learning-based algorithm with instrumental analysis using mass spectrometry to create an expeditious platform that discriminate COVID-19 in plasma samples within minutes, while also providing tools for risk assessment, to assist healthcare professionals in patient management and decision-making. A cross-sectional study with 728 patients (369 confirmed COVID-19 and 359 controls) was enrolled from three Brazilian epicentres (São Paulo capital, São Paulo countryside and Manaus) in the months of April, May, June and July 2020.

We were able to elect and identify 21 molecules that are related to the disease's pathophysiology and 26 features to patient's health-related outcomes. With specificity >97% and sensitivity >83% from blinded data, this screening approach is understood as a tool with great potential for real-world application.

**Keywords:** machine learning; mass spectrometry; COVID-19; screening; diagnostics; risk; metabolomics

#### INTRODUCTION

Coronaviruses (CoVs) are enveloped, single-stranded positive RNA viruses from the *Coronaviridae* family (1). The recent pandemic, caused by a newly discovered strand of coronavirus, SARS-CoV-2, was denominated COVID-19 (2), a disease that disseminated fast and is responsible for hundreds of thousands of deaths worldwide. Measures to control disease spread have led most countries to adopt social distancing and population screening (3). Given its global economic, sanitary and social impact, thousands of new studies aiming to understand viral pathology and targets for virus dissemination control are being conducted, which directly impact in strategies to provide treatments, vaccines, screening tests and patient prognosis.

Special efforts have been directed towards the development of alternatives for mass testing with population-wide capabilities. Currently, available tests are based on the direct detection of SARS-CoV-2 virus through antigens or RNA amplification (RT-PCR), serological tests to evaluate

patient immunity, and the combination of RT-PCR and chest CT (computed-tomography).

COVID-19 testing urgency comprises the need for medical decision-making tools for patient's risk stratification and management, which is poorly achieved by standard methodologies. Even though the basis for these procedures are well-documented in the literature, there are increased concerns about test's sensitivity and specificity achieved on the field, time and costs associated with procedures, reagents and trained personnel availability, and the testing window (4-6).

Difficulties for an accurate diagnosis of SARS-CoV-2 and patient's risk categorization are consequences of COVID-19 complexity. SARS-CoV-2 infection pathophysiology reflects in a broad spectrum of patient symptoms, ranging from mild flu-like manifestations, such as fever, cough, and fatigue, to life-threatening acute respiratory distress syndrome (ARDS), vascular dysfunction, and sepsis (2, 7). In an effort to eliminate the pathogen, the body response to SARS-CoV-2 severe pulmonary infection involves the reduction of natural killer (NK) cells, increased pro-inflammatory cytokines (IL-6, IFN- $\gamma$ , TNF $\alpha$  and others) and lung infiltration, especially by macrophages and monocytes (2, 7, 8), possibly resulting in tissue damage and organ injury (8, 9).

Furthermore, changes in lipid homeostasis, a common characteristic of viral infections, have been associated with SARS-CoV-2 pathology (9-11). In lipidomic and metabolomic profiling of plasma samples, Song et. al. (2020) suggested that exosomes enriched with monosialodihexosyl ganglioside (GM3) are associated with the severity of COVID-19. In the same study, the decrease of circulating acyl-carnitines indicates disturbance in oxidative stress and cellular energy support (9). Moreover, Fan et al. (2020) proposed the relationship between progressive decrease in serum low-density lipoprotein (LDL) and cholesterol within deceased patients (10). Moreover, individual susceptibility to COVID-19 symptoms are not fully understood, thereby hampering any potential outcome prediction.

Panels of biomarkers that translate disease pathophysiology and contribute to SARS-CoV-2 detection may be proposed through "omics" techniques (9, 11, 12). The current trend in associating

artificial intelligence-explained algorithms and "omics" techniques has yielded platforms involving machine learning (ML) to analyze mass spectrometry (MS) data, aiming at biomarker identification of diseases, including COVID-19 severity assessment (11, 13). However, applying traditional untargeted mass spectrometry for diagnostic purposes is laborious, since it requires further method development and validation steps (13, 14).

Considering that the testing tool for COVID-19 introduced in this contribution is based on metabolites from actual patients, it may be considered a new approach for SARS-CoV-2 screening. The proposed end-to-end mass spectrometry and machine learning combination aims at predictively identifying and modeling putative biomarkers for COVID-19 identification and risk assessment. This is critical for effective implementation on a real-world setting, adding robustness to the model in spite of variations in the input data; issues due to noise and minor different variations in acquisition conditions will, therefore, not play a major interference in the final output. Therefore, using the potential of MS-ML techniques in COVID-19 fighting (15), we enrolled a cohort of 728 individuals for the development of this independent platform that simultaneously functions as an automated screening test using plasma samples with high specificity and sensitivity, and provides metabolic information related to the presence and severity risk for the disease.

#### **METHODS**

#### Study design and patient recruitment

Participants were recruited from selected sites with proven expertise in research and high volume of patients with COVID-19 to increase data variability: Central Institute of the Clinical Hospitals, University of São Paulo Medical School (localized in São Paulo, capital of the São Paulo State), Sumaré State Hospital (localized in the state of São Paulo inland), and Hospital Delphina Rinaldi Abdel Aziz (localized in Manaus, capital of Amazonas State localized in the North of the country). The study was conducted according to principles expressed in Declaration of Helsinki and approved by local Ethics Committees (CAAE 32077020.6.0000.0005, CAAE 31049320.7.1001.5404 and CAAE 30299620.7.0000.0068). Inclusion criteria for COVID-19 group (CV) were adult patients with

one or more clinical symptoms of SARS-CoV-2 infection in the last seven days (fever, dry cough, malaise and/or dyspnea) and positive SARS-CoV-2 RT-PCR in nasopharyngeal samples, following local hospital testing protocols based on Charité protocol and WHO recommendations (16). A control group (CT) was formed by symptomatic RT-PCR-negative participants (SN) with SARS-CoV-2 discarded by clinical and tomographic picture, and non-infected controls (AS).

In this study, 728 participants were included, classified according to symptoms, RT-PCR testing results and respective risk (*Figure 1a*). CV was composed of 487 plasma samples from 369 symptomatic SARS-CoV-2 confirmed cases upon hospital arrival, and 118 samples representing a second collection from hospitalized patients (median 11 days, SD 3.8) that recovered (R) or deceased (D). The high-risk group (HRSP) comprised patients with moderate and severe symptoms that required hospitalization (n = 197) and the low-risk (LRSP) category (n = 172) contained those with mild symptoms redirected to home care. Gender, age, and fasting restrictions were not applied, to simulate real-world conditions and to provide results with no patient bias. CT group was formed by 29 SN and 330 AS, totaling 359 individuals *Table S1* (supplementary material) shows detailed demographic information and participant breakdown.

## Mass spectrometry sample preparation

Plasma samples from peripheral venous blood were frozen at -80°C until analysis. A 20- $\mu$ L aliquot of each participant plasma was diluted in 200  $\mu$ L of tetrahydrofuran, followed by homogenization for 30 seconds at room temperature. Thus, 780  $\mu$ L of methanol was added followed by a second homogenization for 30 seconds and centrifugation for 5 min, 3400 x rpm at 4°C. An aliquot of 5  $\mu$ L of the supernatant was diluted in 495  $\mu$ L of methanol and positively ionized by the addition of formic acid (0·1% final concentration) prior to direct infusion in a high-resolution mass spectrometer.

## Mass spectrometry analysis and biomarker elucidation

Samples from CT and CV groups were randomized for data acquisition intra- and inter-daily.

Samples were directly infused in a HESI-Q-Orbitrap®-MS (Thermo Scientific, Bremen, Germany)

and scanned with 140,000 FWHM of mass resolution on positive ion mode. MS parameters were set as follows: m/z range 150- 1,700, 10 mass spectral acquisition per sample, sheath gas flow rate five units, capillary temperature 320°C, aux gas heater temperature 33°C, spray voltage 3·70 kV, automatic gain control (AGC) at  $1 \times 10^6$ , S-lens RF level 50, and injection time < 2 ms. After machine leaning modeling, the presence of each discriminant m/z determined by the algorithm was confirmed in mass spectra using Xcalibur 3.0 software (Thermo, Bremen, Germany). Molecule identification was proposed using METLIN (Scripps Center for Metabolomics, <a href="https://metlin.scripps.edu">https://metlin.scripps.edu</a>), HMDB (Human Metabolome Database, <a href="http://www.hmdb.ca/">http://www.hmdb.ca/</a>) and LIPIDMAPS (Lipidomics Gateway, <a href="https://lipidmaps.org">https://lipidmaps.org</a>) databases and literature search with mass accuracy  $\leq 5$  ppm.

Biomarker pathway analysis and meaning were attributed based on Kegg database (Kyoto Encyclopedia of Genes and Genomes, <a href="https://www.genome.jp/kegg/">https://www.genome.jp/kegg/</a>) information and scientific literature.

#### Machine learning data analysis

The MS-ML platform presented in this study for COVID-19 automated diagnosis and risk determination consists of two primary data analysis phases. The first phase comprises developing a machine-learning model (ML) using a classification algorithm over MS data to determine potential m/z biomarkers for diagnosis and risk determination. The second phase entails a prediction model for diagnosing and determining a high-risk versus low-risk program, which will be used for individuals screening in the field.

Data processing is divided into the sequential steps described in *Figure 1*. First, mass spectrometric data are pre-processed for ion annotation (intensity, width, resolution, and m/z values), alignment, normalization, and denoising. Three different partitions of resulting data are segregated according to the best practices of machine learning, consisting of a fitting partition (training and

validation, shuffled in all ten rounds of ML experiments), test partition, and blind test. The final classification results are reported using the blind partition (see process in *Figure 1a*).

The most discriminant features are determined using the ML algorithms (ADA Tree Boosting (ADA), Gradient Tree Boosting (GDB), Random Forest (RF), and Extreme Random Forest (XRF), which are based on decision trees. In addition, we also explored the Partial Least Squares (PLS) method, which is a linear space transformation (17-19) ), in which a recursive fitting is applied to training and validation data (see *Figure 1b*), with the annotation of averaging and computing the related standard deviation of selected performance metrics.

In all experiments, we adopted the performance metrics defined in *Table S2* (supplementary material) for each round of validation (optimized through accuracy, F1score, MCC). After the observation of performance metrics versus ranked features length, discriminant *m/z* features are evaluated through ΔJ importance (see *Table S2* and *Figure 2a*) and selected for metabolomics biomarkers identification (see section *Mass Spectrometry Analysis and Biomarker Elucidation*). The marker importance is given by a cumulative distribution function (CDF) analysis: for a specific m/z, a CDF of the feature values for the negative samples (CT group) is compared with the CDF of positive samples (CV group) used in the fitting partition.

The CDF comparison uses first the Kolmogorov-Smirnov (KS-test) two samples equality hypothesis test to determine whether those distributions are different (failed on equality hypothesis). Then the  $\mathbb{Z}J$  metric defined in *Table S2* is used to determine if the features contribute negatively  $\mathbb{Z}J$  < 0, which means the negative samples (CT) have a higher probability of presenting higher values over the median of negatives, or positively  $\mathbb{Z}J$  < 0, which means that the positive samples (CV) have a

higher probability of presenting higher values over the median of positives. Features are discarded if CDFs are equal according to KS-test or  $\mathbb{Z}J = 0$ . The selected biomarkers undergo a second round of training and validation with the algorithms mentioned above with the development software (*Figure 1b*, see testing results in *Tables 2* and 3). As putative biomarkers are validated through the development process, they are submitted to the second phase of the machine-learning process targeting the final model to deliver an applied untargeted metabolomics diagnosis software. In this phase, a pairwise model is created (*Figure 1b*), where the relationship between the putative biomarkers are used instead of their intensity (or relative abundance) provided in each spectrum.

## **RESULTS**

## COVID-19 testing through MS-ML platform: modeling and performance

The full dataset resulting from the spectrometer acquisition has 846 biological samples, with ten replicates each, on average. *Table 1* shows the data preparation for the fitting process (shuffled in 10 rounds of training and validation), and testing.

In this study, we employed a novel sequential processing of metabolomics data with Machine-Learning algorithms for building a model divided into two phases. First, a predictive modeling for putative biomarker identification. Then, a combination of biomarker features into relative pairs, composing the predictive model used by the diagnosis and risk assessment in the field (recursive fitting shown in *Figure 1b*).

The analysis for diagnosis was performed with the full dataset, while the risk assessment relied on 369 COVID-19 positive subjects, as this is a second-stage analysis. Out of the COVID-19 positive subjects, 197 achieved local clinical criteria for hospitalization while the remaining 172 individuals were forwarded to homecare. *Tables 2* and *3* show results for the pairwise features for COVID-19 automated diagnosis and risk assessment classifiers, respectively. The best results were obtained with Gradient Tree Boosting (GDB): COVID-19 automated diagnosis with 97.6% of specificity and 83.8% of sensitivity, and risk assessment with 76.2% of specificity and 87.2% of sensitivity, both in the blind test.

Panel of discriminant metabolites for COVID-19 patients using untargeted metabolomics

Thirty ions were selected by the ML method and used for COVID-19 diagnosis using the introduced pairwise model (see *Table 3* for metrics) and further validated through mass spectrometric data. From those, we proposed 21 discriminant biomarkers for COVID-19 condition, divided into ten with positive (mean values higher for the positive group) and 11 with a negative contribution to the condition. Out of 21 molecules, eight belong to the glycerophospholipid class, three glycerolipids, three fatty acids, two cholesterol derivatives, one purine metabolite, one prostanoid, one plasmalogen, and two unknown peptides. The remaining ten molecules have not yet been identified, a common element of non-targeted metabolomics (14). Valid biomarkers and unknown features are available in *Table 4*.

For risk assessment, 26 ions were used to achieve the metrics displayed in *Table 4*. Among them, nine biomarkers contributed to the COVID-19 higher risk condition and 17 biomarkers contributed to

lower risk. The main findings shown in *Table 4* pointed to a relative reduction of certain species of lysophosphatidylcholine (LysoPC), phospholipids, cholesteryl ester (CE) and triacylglycerols (TG) in moderate/severe cases in comparison to patients with mild symptoms (*Figure 2a*). In *Table 4* the biomarkers were first grouped by type of contribution, followed by metabolic class/function and importance reflected through  $\square J$  metric. A representation of biomarkers class and  $\Delta J$  metrics are displayed in *Figure 2a*.

## **DISCUSSION**

#### MS-ML elected biomarkers and COVID-19 pathophysiology

The use of AI-explained algorithms allowed us to create reliable models that facilitate decision-making in clinics and the investigation of the pathophysiological meaning of the distinct biomarker's levels. Viral recognition is an essential step for initial host immune response, and the rapid course and cytokine storm associated with SARS-CoV infection may be involved with the guanosine- and uridine-rich (GU) single-strand RNA potential role as PAMP (pathogen-associated molecular patterns) (1). Deoxyguanosine [268·1050, [M+H]<sup>+</sup>), a metabolite from purine metabolism (Kegg hsa00230), triggers the enhanced signalling of TLR7 in the presence of ssRNA, inducing cytokine secretion in macrophages (20). Therefore, further investigations are required to understand the potential role of deoxyguanosine in SARS-CoV-2 immune hyperactivation and pathology.

The main lipidic findings pointed to a remodelling of glycerophospholipid metabolism. We identified enhanced presence of phosphatidylglycerol (PG) [PG(35:4), PG(35:1), PG(33.1)] and phosphatidylethanolamine (PE) [PE(38:4)], and a diminishment of lysophosphatidylcholines (LysoPC) [LysoPC(16:0), LysoPC(16:1), LysoPC(18:0), LysoPC(18:2)] and phospatidylserine plasmalogens (PS-PL) (21) [PS(O-36:2) and/or PS(P-36:1)] in COVID-19 positive patients, as illustrated in *Figure 2a* by glycerophospholipid pathway recurrence.

LysoPCs [LysoPC(16:0) and LysoPC(18:2)] were also found as negative contributors in plasma samples from patients who required hospitalization (moderate and severe cases). Cell responses to various stimuli may be mediated by phospholipids, which actively participates in inflammation processes. The relative intensities decrease of Lysophosphatidylcholines in positive and, and some of them, in moderate to severely-ill patients, are in accordance with recent studies of metabolic changes in acute respiratory distress syndrome (ARDS) and sepsis (22, 23), important characteristics of COVID-19 severity (2, 7).

LysoPC is formed through the cleavage of PC mediated by phospholipase A2, (PLA2), whose modulation has a crucial role in inflammation processes (see LysoPCs' related pathways in *Figure* 2b). PLA<sub>2</sub> up-regulation promotes fatty acids formation, precursors of eicosanoids, and LysoPCs (24). Data show that SARS-CoV nucleocapsid protein stimulates the expression of Ciclooxygenase-2 (COX-2), an essential enzyme in the catalyses of prostanoids production from fatty acids, as those found at m/z 407.1821 in positive group (25). Although we identified an ion correlated to eicosanoid biosynthesis that indicates PLA<sub>2</sub> and COX-2 activity in positive patients, LysoPCs were relatively decreased in this group. The availability of LysoPCs is also finely regulated by the acyltransferase activity of LCAT (Lysophosphatidylcholine Acyltransferase 1), which may promote the restoration of PCs via Lands cycle. The most abundant lipid species found in alveolar surfactant formed by LCAT1 activity over LysoPC is Dipalmitoylphosphatidylcholine (DPPC, PC(16:0/16:0)). This molecule corresponds to 70-80% of surfactant lipid composition, and the dysregulation of surfactant film is directly related to lung injury and ARDS (24). Since DPPC formation is dependent on the availability of lipid substrates and the Lands cycle functioning, interferences in this process may disturb LysoPC availability. In a metabolomic study, Ferrarini et al (2017) described a decrease in LysoPC species and increased MG(18:1) [m/z 379.2807] in serum of patients with ARDS derived from Influenza infection and sepsis, reinforcing our findings (22).

Moreover, COVID-19 pathophysiology seems to impair cholesterol homeostasis (9, 10). We found cholesteryl ester (CE) associated with mild symptoms, which was similarly reported by Song et. al (2020). They demonstrated the correlation between CE abundance and BMP(38:5), a lipid that influences cellular exportation of cholesterol from endosomes. During recovering progression, it was

found an increased alveolar macrophages BMP with enhanced CEs (9). Cholesterol and LDL (low-density lipoprotein) lowering was also observed in clinical practice associated with COVID-19 poor prognosis (10), such as triacylglycerol in ARDS (26).

Herein, based on the proposed m/z ions we discriminated COVID-19 patients using a diagnostic and risk assessment classifier generated from a MS-ML combination. Although the proposed biomarkers correlates COVID-19 pathophysiology to the mathematical process, a more comprehensive biomarker evaluation is needed to better understand their contribution to COVID-19, and identify the unknowns.

Use of untargeted metabolomics and ML for automated COVID-19 diagnosis and risk assessment

The combination of artificial intelligence algorithms for biomarker mining in complex data is a common approach for problem-solving and implementing new technologies in health sciences. The use of machine learning as a mean for the discrimination of diseases from mass spectrometric data aims to develop diagnostic and prognostic biomarkers, treatment targets and patient management systems (13).

Our methodology introduced the pairwise m/z analysis, an essential advance in untargeted metabolomics application. By combining different m/z, this approach supports the spectra acquired by different mass spectrometers, including the robust use of flow-injection mass spectrometry (FI-MS), in an effort to overcome the ion competition effect (27).

The model optimization with pairwise features can be easily transferred to an independent diagnosis platform. Given that the process key is available from biological sample "ion-fishing", this

approach does not require chromatography and biomarkers quantitation for independent diagnosis.

Moreover, the proposed MS-ML platform for COVID-19 presented reliable qualitative results, with specificity of 97.6% and sensitivity of 83.8% (in a blind test data), similar or even better in performance when compared to available serology (5) and RT-PCR methods (6). Our analysis also brings molecular information about disease pathophysiology that may aid in prognostic markers and treatment targets for COVID-19. Overall, our test aggregates, in one solution, an alternative for populational COVID-19 screening and guidance for public health efforts through risk classification. The same approach may be applied to other diseases involved with patient management during the pandemic and contribute to the COVID-19 MS Coalition's collective effort (15) by consolidating the combination of mass spectrometry and artificial intelligence in a real-world setting.

#### **REFERENCES**

- 1. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes and infection. 2013;15(2):88-95.
- 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 3. Coronavirus Disease (COVID-19) Dashboard [Internet]. World Health Organization. 2020 [cited 2020/7/4]. Available from: https://covid19.who.int/.
- 4. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reproductive BioMedicine Online. 2020.
- 5. Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public health. 2020.
- 6. Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. Journal of medical virology. 2020.
- 7. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020.
- 8. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology. 2020:108393.

- 9. Song J-W, Lam SM, Fan X, Cao W-J, Wang S-Y, Tian H, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metabolism. 2020.
- 10. Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;In press:154243.
- 11. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020.
- 12. Ihling C, Tänzler D, Hagemann S, Kehlen A, Hüttelmaier S, Arlt C, et al. Mass spectrometric identification of SARS-CoV-2 proteins from gargle solution samples of COVID-19 patients. Journal of Proteome Research. 2020.
- 13. Liebal UW, Phan AN, Sudhakar M, Raman K, Blank LM. Machine Learning Applications for Mass Spectrometry-Based Metabolomics. Metabolites. 2020;10(6):243.
- 14. Naz S, Vallejo M, García A, Barbas C. Method validation strategies involved in non-targeted metabolomics. Journal of Chromatography A. 2014;1353:99-105.
- 15. Struwe W, Emmott E, Bailey M, Sharon M, Sinz A, Corrales FJ, et al. The COVID-19 MS Coalition—accelerating diagnostics, prognostics, and treatment. The Lancet. 2020.
- 16. Corman V, Bleicker T, Brünink S, Drosten C, Zambon M. Diagnostic detection of 2019-nCoV by real-time RT-PCR. World Health Organization, Jan. 2020;17.
- 17. Bishop CM. Pattern recognition and machine learning: springer; 2006.
- 18. Géron A. Hands-on machine learning with Scikit-Learn, Keras, and TensorFlow: Concepts, tools, and techniques to build intelligent systems: O'Reilly Media; 2019.
- 19. Murphy K. Machine learning: a probabilistic perspective. Cambridge, Mass.[ua]. MIT Press; 2013.
- 20. Davenne T, Bridgeman A, Rigby RE, Rehwinkel J. Deoxyguanosine is a TLR7 agonist. European journal of immunology. 2020;50(1):56-62.
- 21. Ivanova PT, Milne SB, Brown HA. Identification of atypical ether-linked glycerophospholipid species in macrophages by mass spectrometry. Journal of Lipid Research. 2010;51(6):1581-90.
- 22. Ferrarini A, Righetti L, Martínez MP, Fernández-López M, Mastrangelo A, Horcajada JP, et al. Discriminant biomarkers of acute respiratory distress syndrome associated to H1N1 influenza identified by metabolomics HPLC-QTOF-MS/MS platform. Electrophoresis. 2017;38(18):2341-8.
- 23. Drobnik W, Liebisch G, Audebert F-X, Fröhlich D, Glück T, Vogel P, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. Journal of lipid research. 2003;44(4):754-61.
- 24. Cañadas O, Olmeda B, Alonso A, Pérez-Gil J. Lipid–Protein and Protein–Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis. International Journal of Molecular Sciences. 2020;21(10):3708.
- 25. Yan X, Hao Q, Mu Y, Timani KA, Ye L, Zhu Y, et al. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. The international journal of biochemistry & cell biology. 2006;38(8):1417-28.
- 26. Maile MD, Standiford TJ, Engoren MC, Stringer KA, Jewell ES, Rajendiran TM, et al. Associations of the plasma lipidome with mortality in the acute respiratory distress syndrome: a longitudinal cohort study. Respiratory research. 2018;19(1):1-8.
- 27. Sarvin B, Lagziel S, Sarvin N, Mukha D, Kumar P, Aizenshtein E, et al. Fast and sensitive flow-injection mass spectrometry metabolomics by analyzing sample-specific ion distributions. Nature Communications. 2020;11(1):1-11.

## **ACKNOWLEDGMENTS**

The authors would like to thank the network involved in sample collection, clinical and diagnosis support, and Thermo Scientific and LADETEC (UFRJ) for technology support.

## **FUNDING**

This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to J.D., 2018/10052-1 to W.J.F., 2020/04705-2 to R.F.S., 2020/05369-6 to F.M.T.C., and 2020/04305-2 to J.C.N. and T.F.D.], Amazonas State Government, Superintendence of the Manaus Free Trade Zone (SUFRAMA), Coordination for the Improvement of Higher Education Personnel (CAPES), Department of Science and Technology (DECIT) -Brazilian Ministry of Health (MS), Ministry of Science, Technology and Innovation - National Council for Scientific and Technological Development (CNPq) [grant 403253/2020 to M.V.G.L.]

#### **AUTHOR CONTRIBUTIONS**

R.S.F., J.C.N., T.F.D., A.J.B., E.C.S., L.O.R., W.J.F., M.W.P.J., M.V.G.L., G.C.M., W.M.M., F.F.A.V., D.B.S., V.S.S., J.D., and R.R.C were involved with study design and ethics approval. R.S.F., T.F.D., A.J.B., R.S., E.C.S., A.E., L.O.R., W.J.F., N.D., L.A.S, J.C.C.A., M.V.G.L., G.C.M., W.M.M., F.F.A.V., R.L.A.N., D.B.S. and V.S.S. contributed to patient data acquisition and analysis, clinical support and network feasibility. L.C.N., J.D., A.R.R. and R.R.C., conceived and developed the MS-ML method. J.D., E.N.BB., G.M.S., A.N.O., D.N.O. performed mass spectrometry experiments and data interpretation. J.D., L.C.N., R.F.S. prepared tables, figures and wrote the manuscript. E.N.B.B., G.M.S., A.N.O., D.N.O., F.T.M.C., N.D., W.F.J., L.O.R., D.B.S., F.F.A.V., W.M.M., G.C.M., J.C.N., A.R.R. and R.R.C. revised the manuscript. RRC idealized the project and managed the research group. All authors read and approved the manuscript.

# ADDITIONAL INFORMATION

#### **Competing Interests**

The authors declare no competing interests.

#### Data availability

The data generated in this study will be anonymized to attend patient's privacy restrictions and will be available from corresponding authors upon request after publication.

#### FIGURES AND TABLES

Figure 1 End to end process for putative biomarkers determination and diagnosis test generation. a) Based on clinical symptoms and diagnosis results, subjects were grouped in low-risk symptomatic positive (LRSP), high-risk symptomatic positive (HRSP), recovered (R) or deceased (D), symptomatic negative (SN) and asymptomatic negative (AN). Samples were prepared injected in a high-resolution mass spectrometry (HR-MS) equipment for data acquisition and datasets generated for data analysis according to the partitions; b) Sequential steps of machine learning data analysis and metabolomics biomarkers determination were followed for diagnosis model generation and deployment.

*Figure 2* Putative biomarkers elucidation and related class/ pathways. a) Recursive fitting of mass spectra data followed by model optimization processes allowed the determination of putative biomarkers ranked by DeltaJ importance and group contribution. b) Proposed role of identified biomarkers in COVID-19 pathophysiology. Abbreviations: ARDS – acute respiratory distress syndrome, COX-2 – cyclooxygenase-2, DeoxyGU, deoxyguanosine, LPCAT1 – lysophosphatidylcholine acyltransferase 1, LysoPC – lysophosphatidylcholine, PC – phosphatidylcholine, PLA<sub>2</sub> – Phospholipase A<sub>2</sub>

**Table 1** Dataset subdivisions for model fitting (training and validation), testing and blind test for COVID-19 diagnosis and risk assessment.

Model	COVID	-19 diagnos	sis (n= 846)	COVID-19 risk assessment			
Class	Positive Negative Subtotal High-risk		Low-risk	Subtotal			
Fitting - Training	219	195	414 on avg. (49%)	96	92	188 on avg. (51%)	
Fitting - Validation	89	79	168 on avg. (20%)	39	37	76 on avg. (21%)	
Testing	49	44	93 (11%)	23	22	45 (12%)	
Blind Test	130	41	171 (20%)	39	21	60 (16%)	

**Table 2** Performance metrics for diagnostics model using pairwise features on the 10 validation tests with 6 different classifier algorithms for Covid-19 positive/negative diagnosis, final development testing and deployed software blind test. Numbers correspond to individual's classification average and standard deviations in parenthesis.

Model		COVID-1	9 diagnosis d	levelopment	validation		Test	Blind Test
Algorithms	ADA	GDB	RF	XRF	PLS	SVM	GDB	GDB
Vector length	39	39	39	39	39	39	39	39
# of Estimators	260 (3)	260 (3)	260 (3)	260 (3)	NA	NA	256	256
TN	73 (3)	72 (3)	70 (3)	69 (3)	67 (4)	71 (3)	42	41
FP	7 (2)	7 (2)	9 (3)	11 (3)	12 (3)	8 (2)	2	1
FN	5 (2)	4(1)	10 (4)	7 (2)	7 (2)	9 (2)	3	21
TP	84 (4)	85 (3)	79 (4)	83 (3)	82 (3)	80 (4)	46	109
Accuracy (%)	93.0 (1.6)	93.5 (1.6)	88.6 (2.2)	89.7 (2.0)	88.5 (1.8)	90-1 (1-6)	94.7	90.7
Sensitivity (%)	94.2 (2.1)	95.4 (1.3)	88.4 (4.0)	92.7 (2.2)	92.3 (2.0)	90.2 (2.6)	93.9	83.8
Specificity (%)	91.7 (2.6)	91.5 (2.4)	88.7 (3.1)	86.7 (3.4)	84.7 (3.8)	90.0 (2.8)	95.5	97.6
Precision (%)	92.0 (2.4)	91.8 (2.2)	88.8 (2.7)	87.6 (2.8)	85.9 (2.9)	90.1 (2.5)	95.4	97.2
F1 Score (%)	93-1 (1-5)	93.6 (1.5)	88.5 (2.3)	90.0 (1.9)	88-9 (1-6)	90.1 (1.5)	94.6	90.0
MCC	0.86 (0.05)	0.87 (0.05)	0.77 (0.05)	0.79	0.77 (0.06)	0.80 (0.05)	0.89	0.82
				(0.06)				

**Table 3** Performance metrics for the risk assessment model using pairwise features on the 10 validation tests with six different classifier algorithms, final development testing, and deployed software blind test. Numbers correspond to individual's classification average and standard deviations in parenthesis.

Model		Risk assessm	Test	Blind Test				
Algorithms	ADA	GDB	RF	XRF	PLS	SVM	GDB	GDB
Vector length	33	33	33	33	33	33	33	33
# of Estimators	260 (3)	260 (3)	68 (3)	260 (3)			256	256
TN	31 (3)	31 (3)	30 (3)	30 (3)	31 (3)	31 (4)	15	16
FP	6 (2)	6 (3)	7 (3)	7 (3)	6 (3)	6 (4)	7	5
FN	6 (2)	6 (2)	9 (2)	9 (2)	9 (2)	8 (2)	2	5
TP	33 (2)	33 (2)	30 (2)	30 (2)	30 (2)	31 (2)	21	34
Accuracy (%)	84.2 (4.1)	84.5 (4.1)	79-2 (4-2)	79.4 (3.9)	80.5 (4.2)	81.2 (5.0)	79.7	81.7
Sensitivity (%)	84.3 (5.5)	85.3 (4.0)	77.9 (5.4)	77-1 (4-9)	77.0 (5.0)	78.7 (5.8)	91.3	87.2

Specificity (%)	84.2 (5.8)	83.7 (7.3)	80.5 (8.2)	81.7 (6.6)	84.1 (8.2)	83.7 (9.4)	68.2	76.2
Precision (%)	84.4 (5.0)	84.3 (5.9)	80.5 (6.3)	81.2 (5.6)	83.5 (6.8)	83.7 (8.2)	74.2	78.5
F1 Score (%)	84.2 (4.2)	84.7 (3.7)	78.9 (3.9)	78.9 (3.8)	79.8 (4.0)	80.8 (4.8)	81.8	82.6
MCC	0.68 (0.11)	0.68 (0.13)	0.58	0.58	0.61	0.63 (0.15)	0.61	0.64
,			(0.12)	(0.10)	(0.13)			

Table 4 Proposed biomarkers to *m/z* discriminant features elected by Machine Learning algorithm group first by model contribution (COVID-19 diagnosis and risk assessment), followed by metabolic function and deltaJ.

Average Exact m/z	DeltaJ	Molecular Formula	Adduct	Error (ppm)	Biomarker	Metlin ID	Kegg ID	Pathway/Function	Ref.
COVID-19 dia	gnosis posi	tive contribution							
774 5259	32.4	$C_{41}H_{73}O_{10}P$	$[M+NH4]^{+}$	-2.71	PG(35:4) ≠	79115	C00244		
785-5267	29.6	$C_{41}H_{79}O_{10}P$	[M+Na]+	-4.58	PG(35:1) ≠	79152	- C00344	Class and the same slimids match aligns	
806-5056	28.6	C <sub>43</sub> H <sub>78</sub> NO <sub>8</sub> P	$[M+K]^+$	-4.96	PE(38:4) ≠	40317	C00350	Glycerophospholipids metabolism	-
752-5441	22.6	C <sub>39</sub> H <sub>75</sub> O <sub>10</sub> P	$[M+NH_4]^+$	0.53	PG(33:1) ≠	78970	C00344	-	
907-7721	29.8	$C_{57}H_{104}O_6$	$[M+Na]^+$	-0.44	TG(54:0) ≠	4947	C00422	Glycerolipids – MG(18:1) was found	(22)
577-5177	18.5	$C_{37}H_{70}O_5$	$[M+H-H_2O]^+$	-3 29	DG(34:1) ≠	4260	C13861	increased in ARDS derived from	
379-2807	12.2	$C_{21}H_{40}O_4$	$[M+Na]^+$	-3 16	$MG(18:1) \neq$	62321	C01885	Influenza infection	
407·1821	28.8	$C_{20}H_{32}O_6$	$[M+K]^+$	-2·21	Prostanoids	3819 3812 74981 3508 36259	C05962 C05956 C05964	Prostanoids – e.g. Hydroxy-PGE2, Keto-PGE1, Hydroxy-PGD2, PGG2 and/or Dehydro-thromboxane B2 §	(25)
268·1050	18·1	$C_{10}H_{13}N_5O_4$	[M+H] <sup>+</sup>	3.73	Adenosine and/or Deoxyguanosine §	86 3395	C00212 C00330	Purine metabolism – SARS-CoV presents guanosine-rich ssRNA fragments that have been associated with cytokine storm. Deoxyguanosine induce type 1 interferon response in macrophages and dendritic cells though TLR7 activation. TLR7 receptors are activated when both ssRNA and deoxyguanosine binds.	(1, 20)
581-3651	38-9	$C_{24}H_{44}N_{12}O_5$	$[M+H]^+$	3.61	Peptide 1§	178173	-	Unknown	-
822-4806	25·1	-	-	-	Unknown 1	-	-	-	-
851-3953	25·1	-	-	-	Unknown 2	-	-	-	-
385-2613	21.7	-	-	-	Unknown 3	-	-	-	-
1171 0891	21.4	-	-	-	Unknown 4	-	-	-	-
673-6592	17.4	-	-	-	Unknown 5	-	-	-	-


429 3718	16.3	-	-	-	Unknown 6	-	-	-	-
605:3154	12.5	-	-	-	Unknown 7	-	-	-	-
376-2597	12.3	-	-	-	Unknown 8	-	-	-	-
COVID-19 di	iagnosis neg	ative contribution	ı						
367·3350	-27:7	C <sub>27</sub> H <sub>44</sub> O	$[M+H-H_2O]^+$	-4.08	Cholesterol derivative 1§	3902	C01164	Precursors of Vitamin D and oxysterols e.g. Dehydrocholesterol, pre-Vitamin D3 and/or Keto-cholesterol	-
408·3087	-15·1	$C_{24}H_{38}O_4$	$[M+NH_4]^+$	-5·14	Cholesterol derivative 2 §	84469	-	Bile acid derivatives e.g. Dihydroxy-cholenoic acid and/or hydroxy-oxo-cholanoic acid (Ketodeoxycholic acid)	-
518-3208	-24.5	$C_{24}H_{50}NO_7P$	$[M+Na]^+$	-1.74	LysoPC(16:0) ≠	61692			
494-3232	-21-9	$C_{24}H_{48}NO_7P \ C_{29}H_{45}NO_4$	$\begin{bmatrix} M+H \end{bmatrix}^+ \\ \begin{bmatrix} M+Na \end{bmatrix}^+ $	-1.82	LysoPC(16:1) ≠ and/or Cervonyl carnitine §	61693 58436		Glycerophospholipid – reduced levels of LysoPCs are found in ARDS and	(7, 9, 21-24)
546-3533	-16-8	C <sub>26</sub> H <sub>54</sub> NO <sub>7</sub> P	[M+Na] <sup>+</sup>	0.55	LysoPC(18:0) ≠ and/or PAF C16 §	61694 34488	C04230	sepsis. Precursor of DPPC (surfactant) Acyl-carnitines - diminished in severely-ill SARS-CoV-2 patients	
520-3387	-13-7	$C_{26}H_{50}O_{7}P$	$[M+H]^+$	-2.11	LysoPC(18:2) ≠	61696		PS-PLs have been detected in	
796-5447	-23.0	C <sub>24</sub> H <sub>80</sub> NO <sub>9</sub> P	[M+Na] <sup>+</sup>	-2.01	$PS(O-36:2) \neq and/or$ $PS(P-36:1) \neq \S$	78675 78831		macrophages.	
430-2432	-18-3	$C_{22}H_{31}N_5O_4$	$[M+H]^+$	-3.95	Peptide 2 §	19676	-	Unknown	-
345-2183	-15.9	$C_{20}H_{34}O_2$	$[M+K]^+$	-2.03	Eicosatrienoic Acid	34828	-		
242.2110	-11-5	$C_{14}H_{24}O_2$	$[M+NH_4]^+$	-2.06	Tetradecadienoic acid	73932	-	Fatty acids – may be derived from membrane phospholipids	(24)
228-1955	-10-3	$C_{13}H_{22}O_2$	$[M+NH_4]^+$	-1.31	Tridecadienoic acid	73920	-	- memorane phospholipius	
423-3072	-21·1	-	-	-	Unknown 9	-	-	-	
266-1721	-16·8	-		-	Unknown 10	-	-	-	
High-risk ma	rkers								
379-2817	10.2	$C_{21}H_{40}O_4$	$[M+Na]^+$	-0.53	MG(18:1) ≠	62329	C01885	Glycerolipids – MG (18:1) was found increased in ARDS derived from Influenza infection	(22)
219-0269	8.9	$C_6H_{12}O_6$	$[M+K]^+$	1.82	Hexose §	63118	C00267	-	-
659-2673	14.9	$C_{31}H_{40}N_8O_6\\$	$[M+K]^+$	-4.40	Peptide 3 §	205477	-	Unknown	-


246.1241	18.5	-	-	-	Unknown 11	-	-	-	-
398-3745	29.1	-	-	-	Unknown 12	-	-	-	-
958-6456	12.0	-	-	-	Unknown 13	-	-	-	-
974-6407	15.9	-	-	-	Unknown 14	-	-	-	-
1073:4946	8.4	-	-	-	Unknown 15	-	-	-	-
1172:7748	9.2*	-	-	-	Unknown 16	-	-	-	-
Low-risk mark	ers								
542.3220	-38-2	$C_{26}H_{50}NO_7P$	$[M+Na]^+$	0.55	LysoPC(18:2) ≠	61696			
496·3402	-23·1	C <sub>24</sub> H <sub>50</sub> NO <sub>7</sub> P C <sub>29</sub> H <sub>47</sub> NO <sub>4</sub>	[M+H] <sup>+</sup> [M+Na] <sup>+</sup>	0·81 1·01	LysoPC(16:0) ≠ And/or Docosapentaenoyl-carnitin e §	61692 58392	C04230	Glycerophospholipid – reduced levels of LysoPCs are found in ARDS and sepsis. Precursor of DPPC (surfactant) Acyl-carnitines are diminished in severely-ill SARS-CoV-2 patients.	(7, 9, 22-24)
822-5127	-18-6*	$C_{41}H_{73}O_{13}P$	$[M+NH_4]^+$	0.49	PI(32:3) ≠	800389	C01194	severely-iii SARS-Cov-2 patients.	
851-7090	-24.9	$C_{53}H_{96}O_{6}$	$[M+Na]^+$	-1.06	TG(50:3) ≠	4753	G00.488	Glycerolipid metabolism –	(26)
877-7264	-15 3*	$C_{55}H_{98}O_{6}$	$[M+Na]^+$	0.91	TG(52:4) ≠	4829	- C00422	polyunsaturated TGs are associated with poor prognosis of ARDS	
671-5733	-24·1	C <sub>47</sub> H <sub>74</sub> O <sub>2</sub>	$[M+H]^+$	-4·16	CE(20:5) ≠	41710	C02530	Sterol – decreased levels of blood LDL and CEs have associated with poor prognosis of COVID-19. CE homeostasis may be impaired due to changes in BMP.	(9, 10)
687·5482	-14-3	$C_{38}H_{71}NO_{8}$	$[M+NH_4]^+$	-5.24	GlcCer(32:2) ≠	103281	C01190	Alterations in sphingolipid metabolism during COVID-19 infection.	(9, 11)
427 3049	-8.0	$C_{20}H_{47}NO_4$	$[M+H-H_2O]^+$	3.74	Peptide 4 §	171019	-	Unknown	-
1008-9089	-30.8	-	-	-	Unknown 17	-	-	Unknown	-
984-9098	-30.4	-	-	-	Unknown 18	-	-	Unknown	-
804-5520	-21.4	-	-	-	Unknown 19	-	-	Unknown	-
410-7622	-17-2	-	-	-	Unknown 20	-	-	Unknown	-
285-1403	-12.0	-	-	-	Unknown 21	-	-	Unknown	-
369-384	-10-6	-	-	-	Unknown 22	-	-	Unknown	-
256-2254	-9.2	-	-	-	Unknown 23	-	-	Unknown	-
1006-6304	-9:0	-	-	-	Unknown 24	-	-	Unknown	-


521	1-3816	-7.2	-	-	-	Unknown 25	-	-	Unknown	-	
3											
4	≠ (Carbo	on number	r : double ł	ond); § Isomers w	ith the same	e exact $m/z$ and similar f	ragmentation j	profile to be	e distinguished by FI-M	IS; *Isotopic selection by ML	
5	model.										
6	Ab	breviation	s: ARDS -	Acute respiratory	distress syr	ndrome; BMP - bis(mon	oacylglyero)pl	hosphate; D	G – Diacylglycerol; DF	PPC –	
7	Dipalmi	toylphosp	hatidylcho	line; GlcCer – Glu	cosylceram	ide; LDL - Low-density	lipoprotein; L	ysoPC – Ly	sophosphatidylcholine	e; MG – Monoacylglycerol; PAF	7
8	– Platele	et Activati	ng Factor;	PC – Phosphatidy	lcholine; PE	E – Phosphatidylethanol	amine; PG-Pho	osphatidylg	lycerol; PI – Phosphatic	dylinositol; PS –	
9	Phospha	ıtidylserin	e; TG – Tr	iacylglycerol.							

# MASS SPECTROMETRIC DATA ACQUISITION AND DATA PREPARATION **a**) COVID-19 CONTROL CV = 369CT = 359**PARTITIONS BLIND TEST** SHUFFLED 10X LRSP(172) SN (29) m/z**FINAL TEST** HRSP (197) AN (330) PRE-PROCESSING **SPECTRA** DATASET **FITTING** MASS SPECTRA R or D (118)











**VALIDATION** 

BIOMARKER IDENTITY PATHWAY INTEGRATION





**DEPLOYMENT** 

**TRAINING** 

**VALIDATION** 

